Abeona Therapeutics (ABEO) director gets 37,313-share restricted stock grant

Rhea-AI Filing Summary

Abeona Therapeutics director receives restricted stock grant. Director Christine Silverstein Berni was awarded 37,313 shares of Abeona Therapeutics common stock on January 26, 2026 at a price of $0.00 per share. All of this restricted stock will vest on January 26, 2027.

Following this grant, she beneficially owns 157,792 shares of Abeona Therapeutics common stock in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverstein Christine Berni

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		37,313(1)	A	$0.00	157,792	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All of the restricted stock will vest on January 26, 2027.

	/s/ Christine Silverstein	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for January 26, 2026?

Abeona Therapeutics reported a grant of 37,313 shares of common stock to director Christine Silverstein Berni. The shares were acquired at a price of $0.00 per share as restricted stock, increasing her direct beneficial ownership to 157,792 shares.

Who is the reporting person in the Abeona Therapeutics (ABEO) Form 4 filing?

The reporting person is Christine Silverstein Berni, a director of Abeona Therapeutics. She filed a Form 4 reporting an award of restricted common stock, which brought her directly owned beneficial holdings to 157,792 shares after the reported transaction on January 26, 2026.

How many Abeona Therapeutics (ABEO) shares did the director acquire in this Form 4?

The director acquired 37,313 shares of Abeona Therapeutics common stock. These shares were issued as restricted stock at a price of $0.00 per share, representing an equity compensation award rather than an open-market purchase of the company’s stock.

What is the vesting schedule for the Abeona Therapeutics (ABEO) restricted stock grant?

All of the restricted stock granted to the director will vest on January 26, 2027. This means the 37,313 awarded shares become fully earned on that date, assuming applicable service or other conditions tied to the award are satisfied as described.

What is the director’s total Abeona Therapeutics (ABEO) share ownership after the transaction?

After the restricted stock grant, the director beneficially owns 157,792 shares of Abeona Therapeutics common stock. The filing states this entire amount is held as direct ownership, reflecting her updated equity position following the January 26, 2026 award.

Was the Abeona Therapeutics (ABEO) restricted stock grant a cash transaction?

No, the restricted stock grant was not a cash purchase. The filing lists a transaction price of $0.00 per share, indicating it is an equity compensation award issued to the director rather than stock bought on the open market.